Vaxcyte Inc.
Group Leader, Analytical Development
Vaxcyte Inc., San Carlos, California, United States, 94071
Company Profile:Vaxcyte, Inc. (Nasdaq: PCVX)
is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella.Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth. Following equity offerings in October 2022 and April 2023, which generated over $1.1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24. These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older. The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children. VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD. Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease.Summary:Looking for an energetic, talented and organized leader to join our Analytical Development team. Primary responsibility for the incumbent will be to lead a team of 4-5 to conduct RD stability studies, to perform assay control qualification and characterization testing. The leader is also responsible for overall Analytical Development lab operation including but not limited to instrument purchase, qualification, maintenance, and troubleshooting, as well as lab safety.Essential Functions:Manage R&D ADQC stability programs, such as but not limited to, providing sampling volume forecast, coordinating with stability group on stability set-down and monitoring each stability pull-point.Manage in-house routine testing, such as stability and release testing, characterization, in-process samples analysis and reference standard qualification. Responsible for the overall quality and compliance of all the testing.Provide technical direction, mentorship and coaching to the analytical development team.Lead the design and interpretation of experiments to analyze raw materials.Keep accurate and detailed records of experiments in laboratory notebooks.Summarize data and communicate to cross functional team such as stability, PD and PM.Represent ADQC to attend X-Functional lab operation alignment meeting led by facility.Work within a team environment and provide support to further team objectives.Requirements:PhD in Chemistry, Analytical Chemistry, Biochemistry, or related field with 8+ years relevant industry experience; MS or BS with 15+ years of industry experience in Pharma/Biotech industry required.Proven leadership skills.Outstanding organization and planning skills.Must be a strong scientific leader who can guide scientists with clear goals of developing analytical methods, and critically and skillfully review and assess analytical methods under development.Proven track record of analytical development leadership for biologics and small molecules, experience with vaccines, carbohydrate, or conjugates is a plus.Extensive expertise in U/HPLC, CE, SDS-PAGE, mass spectrometry, and other analytical technologies as applied to protein analytical method development, troubleshooting and validation for GMP release and stability testing.Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.Experience in protein, carbohydrate, and conjugates analysis is highly desired, for example hands on experience and theoretical understanding of HPAEC-PAD, HPLC/UV/FLD, SEC-LC, SEC-MALS, and colorimetric assays are highly desired.Attention to detail and excellent skills in record keeping/documentation. Critical thinking and ability to analyze data.Strong interpersonal skills: ability to communicate effectively both verbally and in written formats.Ability to work with minimum supervision in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.All Vaxcyte employees require vaccination against COVID-19.Reports to:
Associate Director, Analytical DevelopmentLocation:
San Carlos, CACompensation:The compensation package will be competitive and includes comprehensive benefits and an equity component.Salary Range:
$144,000 – $162,000Send resumes to:
careers@vaxcyte.comVaxcyte, Inc.825 Industrial Road, Suite 300San Carlos, CA 94070We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
#J-18808-Ljbffr
is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella.Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth. Following equity offerings in October 2022 and April 2023, which generated over $1.1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24. These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older. The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children. VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD. Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease.Summary:Looking for an energetic, talented and organized leader to join our Analytical Development team. Primary responsibility for the incumbent will be to lead a team of 4-5 to conduct RD stability studies, to perform assay control qualification and characterization testing. The leader is also responsible for overall Analytical Development lab operation including but not limited to instrument purchase, qualification, maintenance, and troubleshooting, as well as lab safety.Essential Functions:Manage R&D ADQC stability programs, such as but not limited to, providing sampling volume forecast, coordinating with stability group on stability set-down and monitoring each stability pull-point.Manage in-house routine testing, such as stability and release testing, characterization, in-process samples analysis and reference standard qualification. Responsible for the overall quality and compliance of all the testing.Provide technical direction, mentorship and coaching to the analytical development team.Lead the design and interpretation of experiments to analyze raw materials.Keep accurate and detailed records of experiments in laboratory notebooks.Summarize data and communicate to cross functional team such as stability, PD and PM.Represent ADQC to attend X-Functional lab operation alignment meeting led by facility.Work within a team environment and provide support to further team objectives.Requirements:PhD in Chemistry, Analytical Chemistry, Biochemistry, or related field with 8+ years relevant industry experience; MS or BS with 15+ years of industry experience in Pharma/Biotech industry required.Proven leadership skills.Outstanding organization and planning skills.Must be a strong scientific leader who can guide scientists with clear goals of developing analytical methods, and critically and skillfully review and assess analytical methods under development.Proven track record of analytical development leadership for biologics and small molecules, experience with vaccines, carbohydrate, or conjugates is a plus.Extensive expertise in U/HPLC, CE, SDS-PAGE, mass spectrometry, and other analytical technologies as applied to protein analytical method development, troubleshooting and validation for GMP release and stability testing.Knowledge of capillary electrophoresis and/or experience in use of such would be a plus.Experience in protein, carbohydrate, and conjugates analysis is highly desired, for example hands on experience and theoretical understanding of HPAEC-PAD, HPLC/UV/FLD, SEC-LC, SEC-MALS, and colorimetric assays are highly desired.Attention to detail and excellent skills in record keeping/documentation. Critical thinking and ability to analyze data.Strong interpersonal skills: ability to communicate effectively both verbally and in written formats.Ability to work with minimum supervision in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.All Vaxcyte employees require vaccination against COVID-19.Reports to:
Associate Director, Analytical DevelopmentLocation:
San Carlos, CACompensation:The compensation package will be competitive and includes comprehensive benefits and an equity component.Salary Range:
$144,000 – $162,000Send resumes to:
careers@vaxcyte.comVaxcyte, Inc.825 Industrial Road, Suite 300San Carlos, CA 94070We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
#J-18808-Ljbffr